Until now, the associations between osteocalcin and insulin secre

Until now, the associations between osteocalcin and insulin secretion and sensitivity were primarily measured by HOMA values;

however, INK 128 order the model predicts the fasting steady-state glucose and insulin concentrations for a wide range of possible combinations of insulin resistance and β-cell function, and it is difficult to determine the true dynamic function of β-cell insulin secretion. In addition, in subjects with severely impaired β-cell function, HOMA-IR did not represent appropriate insulin resistance status [17], and therefore the agreement between HOMA-IR and clamp-measured insulin sensitivity remains controversial [12]. The current study was unique and powered because we determined the association between plasma osteocalcin levels and insulin sensitivity with OGTT-driven dynamic methods that have been extensively validated against euglycemic clamp methods, and determined the β-cell function Copanlisib with diverse

parameters, including the HOMA-B%, insulinogenic index, AUC insulin/glucose, and disposition index. According to the original observation by Lee et al. [1], osteocalcin regulates insulin sensitivity, at least in part, through adiponectin gene expression. In the current study, the plasma adiponectin levels were significantly different across the osteocalcin tertiles (p < 0.001) and were positively correlated with the indices representing insulin sensitivity, including Matsuda’s, Stumvoll’s, and OGIS indices (data not

shown, all p < 0.01). In multiple linear regression analyses, however, the plasma osteocalcin levels were still significantly associated with improved glucose tolerance and insulin secretion and sensitivity indices even after controlling for the adiponectin levels. Therefore, adiponectin did 4��8C not mediate the association between the osteocalcin level and glucose tolerance and insulin secretion and sensitivity in humans. In addition, we investigated whether or not the plasma osteocalcin level is inversely associated with the development of T2DM. The results indicated that the plasma osteocalcin level is inversely associated with the development of T2DM independent of well-established risk factors for diabetes, such as age, gender, BMI, and baseline fasting plasma glucose level and circulating adipokines including plasma adiponectin and leptin levels. These results suggest that osteocalcin-mediated increased insulin sensitivity may not involve adiponectin gene upregulation in humans but may involve other mechanisms. This is the first report to demonstrate an independent association, especially independent of plasma adiponectin levels, between plasma osteocalcin levels and improved glucose tolerance and insulin secretion and sensitivity. In contrast with our results, Shea et al.

Comments are closed.